멀티플렉스 어세이 세계 시장은 2023년부터 2030년까지 9.0%의 연평균 복합 성장률(CAGR)로 대되어 2030년까지 62억 4,000만 달러에 달할 것으로 예상됩니다.
이 보고서는 광범위한 2차 및 1차 연구와 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석으로 구성되어 있습니다. 이 시장의 성장은 싱글플렉스 분석에 비해 멀티플렉스 어세이의 우월성, 동반 진단에서 멀티플렉스 어세이의 활용, 만성 질환 및 감염성 질환의 유병률 증가, 조기 질병 진단의 중요성에 대한 인식 증가 등 여러 가지 요인에 기인합니다. 그러나 멀티플렉스 어세이 장비의 높은 비용으로 인해 시장 성장을 억제하고 있습니다.
높은 처리량의 자동화된 검사 시스템에 대한 수요 증가와 개인 맞춤형 의료에 대한 관심이 높아짐에 따라 이 시장에서 사업을 운영하는 기업들에게 성장 기회를 제공할 것으로 예상됩니다. 그러나 숙련된 전문가 부족과 교차 반응성 위험은 시장 성장에 큰 도전이 될 것입니다.
이 보고서는 제품 포트폴리오 제공, 지역적 입지 및 업계 선도적인 시장 기업들이 향후 몇 년동안(2020-2023년) 채택한 주요 전략적 개발에 대한 광범위한 평가를 바탕으로 경쟁 환경을 제공합니다. 세계 멀티플렉스 어세이 시장에서 사업을 운영하는 주요 기업으로는 e Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), Merck KGaA (Germany) 등이 있습니다.
(주 : SWOT 분석은 주요 5개사에 대해 기재)
Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User-Global Forecast to 2030
The global multiplex assays market is expected to reach $6.24 billion by 2030 at a CAGR of 9.0% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market is attributed to several factors, the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.
The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.
Among all the types studied in this report, in 2023 protein multiplex assays segment is expected to account for the largest share of the multiplex assays market. Protein multiplex assays are further segmented into bead-based assays and planar assays. In 2023, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Bead-based assays offer a dynamic range of analytes as they are measured using flow cytometry. They are suitable for high-throughput analysis and are much more rapid, making them the preferred alternative to planar assays.
Among all the products studied in this report, in 2023, the consumables segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to the repetitive use of kits, the growing portfolio of disease-specific kits for early diagnosis of diseases, and the increasing product approvals. The continuous advancements in reagents and kits, the development of user-friendly diagnostic kits, and the adoption of multiplex assay kits in clinical and research laboratories positively impact the demand for consumables used in multiplex assays.
Among all the technologies studied in this report, the flow cytometry segment is projected to register the highest CAGR during the forecast period. Flow cytometry is considered an important tool in clinical diagnosis and research & development. It provides a multiparametric analysis of many single cells, which can be used in multiple research areas. Additionally, market players are launching advanced flow cytometers to support growing market needs. For instance, in June 2023, Becton, Dickinson and Company (U.S.) launched a BD FACSDuet to automate sample preparation during clinical flow cytometry diagnostics.
Among all the applications studied in this report, in 2023, the research & development segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to increasing applications of multiplex assays in drug discovery, biomarker profiling, and understanding disease mechanisms. The demand for multiplex assays in research & development is increasing rapidly and is also contributing to the largest share of the segment.
Among all the end users studied in this report, the research & development segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to factors such as the increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of multiplex assays in drug discovery & development, and a growing emphasis on personalized medicine research. The rising spending on R&D by pharmaceutical companies is also contributing to the largest share of this segment.
An in-depth analysis of the geographical scenario of the global multiplex assays market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the multiplex assays market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's large share is attributed to the region's high R&D spending by the pharmaceutical & biotechnology companies for the development of drugs and biomarker identification, increasing prevalence of chronic diseases, rising healthcare expenditure, presence of leading market players in the region, and favorable government initiatives for research & development. According to the U.S. Congressional Budget Office, U.S. pharmaceutical R&D expenditure increased from 91.1 billion in 2020 to 102.3 billion in 2021.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2023). The key players operating in the global multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).
Multiplex Assays Market Assessment, by Type
Multiplex Assays Market Assessment, by Product
Multiplex Assays Market Assessment, by Technology
Note: Other technologies consist of microarray and immunohistochemistry
Multiplex Assays Market Assessment, by Application
Note: Other diseases include neurological diseases, thrombosis, and drug abuse testing.
Multiplex Assays Market Assessment, by End User
Note: Other end users consist of academic institutes & research centers, forensic labs, agriculture companies, and food & beverage companies
Multiplex Assays Market Assessment, by Geography
(Note: SWOT analysis is provided for the top 5 companies)